10-K: iSpecimen Inc. Reports Full Year 2023 Results, Cites Material Weakness in Internal Controls

iSpecimen Inc.'s 2023 annual report reveals a net loss of $11.1 million and a material weakness in internal controls, alongside efforts to enhance its marketplace platform and address financial challenges.

Summary

• iSpecimen Inc. reported a net loss of $11.1 million for the year ended December 31, 2023, compared to a net loss of $10.2 million in 2022.
• The company identified a material weakness in its internal control over financial reporting related to sales tax obligations.
• Revenue decreased by 5% to $9.9 million in 2023, primarily due to a decrease in specimen count, partially offset by an increase in average selling price.
• The company's accumulated deficit reached $59.4 million as of December 31, 2023.
• iSpecimen's supply network includes approximately 234 healthcare organizations and biospecimen providers across 19 countries.
• The iSpecimen Marketplace platform has compiled data on approximately 18 million patient records, 101 million clinical specimen records, and 1.3 million banked specimen records.
• The company delivered more than 210,000 specimens in support of nearly 3,000 unique projects since inception.

Sentiment

Score: 3

Explanation: The document reveals significant financial losses, a material weakness in internal controls, and concerns about the company's ability to continue as a going concern. While there are some positive developments, the overall tone is negative from an investment perspective.

Positives

• The company is actively working to remediate the identified material weakness in internal controls.
• iSpecimen continues to invest in the development of its iSpecimen Marketplace platform.
• The company has a large and diverse supply network of healthcare providers and biospecimen providers.
• Customer retention rates are high, with 88% of top customers from 2022 also procuring specimens in 2023.
• The company has implemented a next day quote system to increase conversion ratios of quotes to purchase orders.

Negatives

• The company has incurred losses since inception and anticipates continuing losses.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's revenue trend is not predictive, making it difficult to forecast future results.
• The company relies on a few customers for a significant portion of revenue.
• The company has incurred losses from sales tax obligations due to not collecting taxes on taxable sales in prior years.
• The company's stock price could be delisted from Nasdaq if it fails to meet continued listing requirements.

Risks

• The company may require additional capital in the future, and an inability to meet these needs could adversely impact operations.
• The company's growth strategy may not prove viable, and it may not realize expected results.
• Security breaches or attacks on the company's platforms could lead to loss of data, litigation, and financial exposure.
• Changes in the healthcare industry, including consolidations and regulatory changes, could affect access to subjects, samples, and data.
• The company's supply chain may not provide adequate resources to quickly respond to requests for specimens.
• The company may lose business to competitors with their own biorepositories and collection centers.
• Failure to comply with data protection regulations could result in fines, penalties, and litigation.

Future Outlook

The company plans to continue to invest in its iSpecimen Marketplace platform, expand its customer and supplier base, and explore new lines of business such as patient recruitment and data licensing. They also plan to reduce expenditures through reductions in their workforce.

Management Comments

• Executive management of the Company continues to review the Company's structure, processes, and resources to evaluate and identify areas for improvement, and has been focused on creating and ensuring a runway for growth and scale for the business.
• We have initiated efforts to decrease our capital and operational expenditures by cutting costs and right sizing the Company through reductions in our workforce.
• We are committed to investing in and developing our technology.
• We now have a key supplier program whereby we proactively engage with the suppliers to promote our business through marketing campaigns and supplier organizations offerings.

Industry Context

The document highlights the fragmented nature of the biospecimen market and iSpecimen's attempt to create a more efficient marketplace. It also notes the increasing demand for human biospecimens due to advances in precision medicine, which is a key driver for the company's business.

Comparison to Industry Standards

• The document notes that most biospecimen providers have less than 5% market share each, and no single provider has more than 20% market share, highlighting the fragmented nature of the industry.
• The company competes with commercial biobanks, specimen brokers, and research services marketplaces, some of which are consolidating and well-capitalized by private equity.
• Unlike some competitors, iSpecimen's marketplace allows researchers to search for specific specimens and data, rather than just identifying service providers.
• The company's technology-based approach is intended to allow it to scale faster than competitors who rely on manual processes.

Management Changes

Corporate Governance

Legal Proceedings

• There is no material litigation, arbitration, or governmental proceeding currently pending against the company or its management team.

Stakeholder Impact

• Shareholders may be concerned about the company's financial losses and the material weakness in internal controls.
• Employees may be affected by the reduction in workforce and changes in compensation.
• Customers may be impacted by any disruptions in the company's supply chain or service quality.
• Suppliers may be affected by changes in the company's procurement practices or financial stability.

Next Steps

• The company plans to continue to invest in the development of its iSpecimen Marketplace platform.
• The company intends to expand its customer and supplier base.
• The company will explore new lines of business such as patient recruitment and data licensing.
• The company will continue to implement its remediation plan to address the material weakness in internal controls.
• The company will continue to evaluate its pricing in order to be more competitive.

Key Dates

Keywords

biospecimens, marketplace, technology, healthcare, research, data, internal controls, financial results, supply chain, revenue